Shannon L Risacher1, Wesley H Anderson1, Arnaud Charil1, Peter F Castelluccio1, Sergey Shcherbinin1, Andrew J Saykin2, Adam J Schwarz2. 1. From the Department of Radiology and Imaging Sciences (S.L.R., A.J. Saykin, A.J. Schwarz), Indiana Alzheimer Disease Center (S.L.R., A.J. Saykin), and Department of Biostatistics (P.F.C.), Indiana University School of Medicine; Eli Lilly and Company (W.H.A., A.C., S.S., A.J. Schwarz), Indianapolis; and Department of Psychological and Brain Sciences (A.J. Schwarz), Indiana University, Bloomington. 2. From the Department of Radiology and Imaging Sciences (S.L.R., A.J. Saykin, A.J. Schwarz), Indiana Alzheimer Disease Center (S.L.R., A.J. Saykin), and Department of Biostatistics (P.F.C.), Indiana University School of Medicine; Eli Lilly and Company (W.H.A., A.C., S.S., A.J. Schwarz), Indianapolis; and Department of Psychological and Brain Sciences (A.J. Schwarz), Indiana University, Bloomington. asaykin@iupui.edu a.schwarz@lilly.com.
Abstract
OBJECTIVE: To test the hypothesis that cortical and hippocampal volumes, measured in vivo from volumetric MRI (vMRI) scans, could be used to identify variant subtypes of Alzheimer disease (AD) and to prospectively predict the rate of clinical decline. METHODS: Amyloid-positive participants with AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 1 and ADNI2 with baseline MRI scans (n = 229) and 2-year clinical follow-up (n = 100) were included. AD subtypes (hippocampal sparing [HpSpMRI], limbic predominant [LPMRI], typical AD [tADMRI]) were defined according to an algorithm analogous to one recently proposed for tau neuropathology. Relationships between baseline hippocampal volume to cortical volume ratio (HV:CTV) and clinical variables were examined by both continuous regression and categorical models. RESULTS: When participants were divided categorically, the HpSpMRI group showed significantly more AD-like hypometabolism on 18F-fluorodeoxyglucose-PET (p < 0.05) and poorer baseline executive function (p < 0.001). Other baseline clinical measures did not differ across the 3 groups. Participants with HpSpMRI also showed faster subsequent clinical decline than participants with LPMRI on the Alzheimer's Disease Assessment Scale, 13-Item Subscale (ADAS-Cog13), Mini-Mental State Examination (MMSE), and Functional Assessment Questionnaire (all p < 0.05) and tADMRI on the MMSE and Clinical Dementia Rating Sum of Boxes (CDR-SB) (both p < 0.05). Finally, a larger HV:CTV was associated with poorer baseline executive function and a faster slope of decline in CDR-SB, MMSE, and ADAS-Cog13 score (p < 0.05). These associations were driven mostly by the amount of cortical rather than hippocampal atrophy. CONCLUSIONS: AD subtypes with phenotypes consistent with those observed with tau neuropathology can be identified in vivo with vMRI. An increased HV:CTV ratio was predictive of faster clinical decline in participants with AD who were clinically indistinguishable at baseline except for a greater dysexecutive presentation.
OBJECTIVE: To test the hypothesis that cortical and hippocampal volumes, measured in vivo from volumetric MRI (vMRI) scans, could be used to identify variant subtypes of Alzheimer disease (AD) and to prospectively predict the rate of clinical decline. METHODS: Amyloid-positive participants with AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 1 and ADNI2 with baseline MRI scans (n = 229) and 2-year clinical follow-up (n = 100) were included. AD subtypes (hippocampal sparing [HpSpMRI], limbic predominant [LPMRI], typical AD [tADMRI]) were defined according to an algorithm analogous to one recently proposed for tau neuropathology. Relationships between baseline hippocampal volume to cortical volume ratio (HV:CTV) and clinical variables were examined by both continuous regression and categorical models. RESULTS: When participants were divided categorically, the HpSpMRI group showed significantly more AD-like hypometabolism on 18F-fluorodeoxyglucose-PET (p < 0.05) and poorer baseline executive function (p < 0.001). Other baseline clinical measures did not differ across the 3 groups. Participants with HpSpMRI also showed faster subsequent clinical decline than participants with LPMRI on the Alzheimer's Disease Assessment Scale, 13-Item Subscale (ADAS-Cog13), Mini-Mental State Examination (MMSE), and Functional Assessment Questionnaire (all p < 0.05) and tADMRI on the MMSE and Clinical Dementia Rating Sum of Boxes (CDR-SB) (both p < 0.05). Finally, a larger HV:CTV was associated with poorer baseline executive function and a faster slope of decline in CDR-SB, MMSE, and ADAS-Cog13 score (p < 0.05). These associations were driven mostly by the amount of cortical rather than hippocampal atrophy. CONCLUSIONS: AD subtypes with phenotypes consistent with those observed with tau neuropathology can be identified in vivo with vMRI. An increased HV:CTV ratio was predictive of faster clinical decline in participants with AD who were clinically indistinguishable at baseline except for a greater dysexecutive presentation.
Authors: Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun Journal: J Nucl Med Date: 2012-11-19 Impact factor: 10.057
Authors: Giovanni B Frisoni; Michela Pievani; Cristina Testa; Francesca Sabattoli; Lorena Bresciani; Matteo Bonetti; Alberto Beltramello; Kiralee M Hayashi; Arthur W Toga; Paul M Thompson Journal: Brain Date: 2007-02-09 Impact factor: 13.501
Authors: Clifford R Jack; Josephine Barnes; Matt A Bernstein; Bret J Borowski; James Brewer; Shona Clegg; Anders M Dale; Owen Carmichael; Christopher Ching; Charles DeCarli; Rahul S Desikan; Christine Fennema-Notestine; Anders M Fjell; Evan Fletcher; Nick C Fox; Jeff Gunter; Boris A Gutman; Dominic Holland; Xue Hua; Philip Insel; Kejal Kantarci; Ron J Killiany; Gunnar Krueger; Kelvin K Leung; Scott Mackin; Pauline Maillard; Ian B Malone; Niklas Mattsson; Linda McEvoy; Marc Modat; Susanne Mueller; Rachel Nosheny; Sebastien Ourselin; Norbert Schuff; Matthew L Senjem; Alix Simonson; Paul M Thompson; Dan Rettmann; Prashanthi Vemuri; Kristine Walhovd; Yansong Zhao; Samantha Zuk; Michael Weiner Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Erin E Franklin; Richard J Perrin; Benjamin Vincent; Michael Baxter; John C Morris; Nigel J Cairns Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Ju-Hee Kang; Magdalena Korecka; Michal J Figurski; Jon B Toledo; Kaj Blennow; Henrik Zetterberg; Teresa Waligorska; Magdalena Brylska; Leona Fields; Nirali Shah; Holly Soares; Robert A Dean; Hugo Vanderstichele; Ronald C Petersen; Paul S Aisen; Andrew J Saykin; Michael W Weiner; John Q Trojanowski; Leslie M Shaw Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Andrew J Saykin; Li Shen; Xiaohui Yao; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Vijay K Ramanan; Tatiana M Foroud; Kelley M Faber; Nadeem Sarwar; Leanne M Munsie; Xiaolan Hu; Holly D Soares; Steven G Potkin; Paul M Thompson; John S K Kauwe; Rima Kaddurah-Daouk; Robert C Green; Arthur W Toga; Michael W Weiner Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Dunja Mrdjen; Edward J Fox; Syed A Bukhari; Kathleen S Montine; Sean C Bendall; Thomas J Montine Journal: Acta Neuropathol Date: 2019-08-07 Impact factor: 17.088
Authors: Mara Ten Kate; Ellen Dicks; Pieter Jelle Visser; Wiesje M van der Flier; Charlotte E Teunissen; Frederik Barkhof; Philip Scheltens; Betty M Tijms Journal: Brain Date: 2018-12-01 Impact factor: 13.501
Authors: Jacob W Vogel; Alexandra L Young; Neil P Oxtoby; Ruben Smith; Rik Ossenkoppele; Olof T Strandberg; Renaud La Joie; Leon M Aksman; Michel J Grothe; Yasser Iturria-Medina; Michael J Pontecorvo; Michael D Devous; Gil D Rabinovici; Daniel C Alexander; Chul Hyoung Lyoo; Alan C Evans; Oskar Hansson Journal: Nat Med Date: 2021-04-29 Impact factor: 53.440